4Wymenga LF, Boomsma JH, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate specific antigen and alkaline phosphatase. BJU Int,2001,88 (3) : 226-230.
5O'Donoghue JM, Rogers E, Grimes H, et al. A reappraisal of serial isotope bone scans in prostate cancer. Br J Radiol, 1993,66 (788) :672-676.
6Benson MC, Whang IS, Pantuek A, et al. Prostate specific antigen density:a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol,1992,147(3Pt2) :815-816.
7Semjonow A, Hamm M, Rathert P. The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed pros tate cancer. Urologe A, 1993, 32(3) :250-253.
4Partin A W, Kattan M W, Subong E N, et al.Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update[J].JAMA.1997,277:1445-1451.
5Birtle A J, Freeman A, Masters J R, et al.Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen(PSA) levels＜10μg/L: the ""PSA negative"" patients[J].Cancer, 2003,98(11):2362-2367.
6Miller D C, Hafez K S, Stewart A, et al.Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base[J].Cancer, 2003,98(6):1169-1178.
7Hermanek P, Sobin L H.Urological tumors: prostate[A].In:International union against cancer(UICC) TNM classification of malignant tumors[C].4thed.New York: Springer Verlag,1992.141-144.
8Miller P D, Eardley I, Kirby R S, et al.Prostate-specific antigen and bone scan correlateion in the staging and monitoring of patients with prostatic cancer[J].Br J Urol, 1992,70:295-298.
9马腾骧.现代泌尿外科学[M].天津科学技术出版社,2001..
10Benson MC,Whang IS,Pantuck A,et al.Prostate specific antigen density:a means of distinguishing benign prostatic hypertrophy and prostate cancer.J Urol 1992;147(3Pt2):815-816
1Jemal A, Siegel R, Ward E, et aL Cancer statistics, 2009. CA Cancer J Clin, 2009 59(4) : 225-249.
2Huttunen H J, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem, 1999, 274(28) : 19919-19924.
3Lalla E, Lmnster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest, 2000, 105(8) : 1117-1124.
4Macaione V, Aguennouz M, Rodolico C, et al. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy. Acta Neurol Scand, 2007, 115(2): 115-121.
5Kuniyasu H, Chihara Y, Kondo H, et al. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep, 2003, 10 (6): 1863-1868.
6lshiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Porstate, 2005, 64 ( 1 ) : 92-100.
7Hermani A, Hess J, De Servi B, et al, Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res, 2005, 11 (14) : 5146-5152.
8Futterer JJ, Barentsz JO, Heijmink SW, et al. Value of 3-T magnetic resonance imaging in local staging of prostate cancer[J]. Top Magn Reson hnag, 2008, 19(6): 285-289.
9Augustin H, Fritz GA, Ehatnmer T, et al. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the partin tables [J]. Acta Radiol, 2009, 9: 562- 569.
10Futterer JJ. MR imaging in local staging of prostate cancer[J]. EJR, 2007, 63: 328-334.
